Table 3.
Criteria | SLN Metastasis ≥ 6 mm, | SLN Metastasis >7 mm |
---|---|---|
| ||
n | 19 | 10 |
| ||
Menopausal status | ||
Pre | 5 | 3 |
Post | 14 | 7 |
| ||
Tumor grade | ||
1 | 4 | 0 |
2 | 9 | 5 |
3 | 5 | 4 |
| ||
Tumor size | ||
T1a-b | 1 | 0 |
T1c | 12 | 6 |
T2 | 6 | 4 |
| ||
ER status | ||
Positive | 18 | 10 |
Negative | 0 | 0 |
| ||
PR status | ||
Positive | 14 | 7 |
Negative | 4 | 3 |
| ||
SLN excised | ||
1 | 2 | 0 |
2 | 7 | 4 |
3 | 4 | 3 |
>3 | 6 | 2 |
| ||
Patients with ≥3 positive SLNs | 1 | 0 |
| ||
Patients with additional + LNs on CALND | ||
0 | 10 | 5 |
1 | 3 | 0 |
2 | 4 | 3 |
3 | 0 | 0 |
>3 | 2 | 2 |
CALND, completion axillary lymph node dissection; ER, estrogen receptor; PR, progesterone receptor; SLN, sentinel lymph node.